

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody

Tré-Hardy, Marie; Wilmet, Alain; Beukinga, Ingrid; Dogné, Jean-Michel; Douxfils, Jonathan; Blairon, Laurent

*Published in:*  
Clinical Chemistry and Laboratory Medicine

*DOI:*  
[10.1515/cclm-2020-0594](https://doi.org/10.1515/cclm-2020-0594)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication](#)

*Citation for pulished version (HARVARD):*  
Tré-Hardy, M, Wilmet, A, Beukinga, I, Dogné, J-M, Douxfils, J & Blairon, L 2020, 'Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody', *Clinical Chemistry and Laboratory Medicine*, vol. 58, no. 8, pp. 1357-1364. <https://doi.org/10.1515/cclm-2020-0594>

#### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Marie Tré-Hardy\*, Alain Wilmet, Ingrid Beukinga, Jean-Michel Dogné, Jonathan Douxflis and Laurent Blairon

# Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody

<https://doi.org/10.1515/cclm-2020-0594>

Received April 26, 2020; accepted May 9, 2020

## Abstract

**Objectives:** Faced with the COVID-19 pandemic and its impact on the availability and quality of both therapeutic and diagnostic methods, the Belgian authorities have decided to launch a procedure for additional evaluation of the performance of serological tests offered for sale on the national territory. This has been proposed with a double aim: (1) an in-depth verification of the analytical and clinical performances presented by the manufacturer and (2) an economy of scale in terms of centralized validation for all the laboratories using the tests subject to evaluation.

**Methods:** A retrospective validation study was conducted including the serum of 125 patients in order to determine the analytical and clinical performances of the LIAISON®SARS-CoV-2 from DiaSorin® detecting anti-SARS-CoV-2 IgG and to compare its clinical performance with the enzyme-linked immunosorbent assay (ELISA) test from Euroimmun®, one of the first commercially available tests allowing the detection of anti-SARS-CoV-2 IgA and IgG.

**Results:** The performances of the LIAISON®SARS-CoV-2 satisfied all the acceptance criteria and provided

“real world” analytical and clinical performances very close to the ones reported by the manufacturer in its insert kit. Comparison between the LIAISON®SARS-CoV-2 and the ELISA method did not reveal any difference between the two techniques in terms of sensitivities and specificities regarding the determination of the IgG.

**Conclusions:** This study reports the validation of the LIAISON®SARS-CoV-2 allowing to detect IgG antibodies specifically directed against SARS-CoV-2. The analytical and clinical performances are excellent, and the automation of the test offers important rates, ideal for absorbing an extension of testing.

**Keywords:** CLIA; COVID-19; ELISA; SARS-CoV-2.

## Introduction

On December 31, 2019, the World Health Organization (WHO) was alerted to the appearance of several cases of pneumonia of unknown origin in the city of Wuhan (China). Few weeks later, the pathogen causing this pneumonia was identified: it is a new coronavirus called SARS-CoV-2, the associated disease being designated by the term COVID-19 [1]. Since then, a global health crisis has set in and the pandemic continues to grow: As of May 6, the virus has already spread to 187 countries and territories [2], the number of confirmed cases exceeds 3.6 million and the number of deaths worldwide stands at 243,401 [3]. The number of cases diagnosed, however, only reflects a fraction of the actual number of infections as a large number of countries only test severe cases.

The diagnosis of SARS-CoV-2 infection is essential for the control of the epidemic, the establishment of protective measures and the therapeutic management of patients. The WHO recommends detection of the viral genome in respiratory samples for the diagnosis COVID-19. However, even if RT-qPCR is considered the “gold standard”, many pre-analytical and analytical limitations have recently been described. First, it has been shown that the sensitivity of this method can vary depending on the quality of the sample, the stage but

---

\*Corresponding author: Marie Tré-Hardy, Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Belgium; Faculty of Medicine, Université libre de Bruxelles, Brussels, Belgium; and Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium, Phone: +32 2 641 48 21, Fax: + 32 2 641 48 24, E-mail: mtrehardy@his-izz.be

Alain Wilmet, Ingrid Beukinga and Laurent Blairon: Department of Laboratory Medicine, Iris Hospitals South, Brussels, Belgium  
Jean-Michel Dogné: Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium  
Jonathan Douxflis: Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium; and Qualiblood sa, Namur, Belgium. <https://orcid.org/0000-0002-7644-5298> (J. Douxflis)

also the severity of the disease, leading to approximately 20% of false-negative cases [4–7].

Furthermore, access to RT-qPCR tests remains limited. Despite significant efforts in Belgium to increase the number of RT-qPCR testing, this method will not alone cover rapid and massive screening of the population.

Considering the health emergency, many cheaper and convenient serological tests have rapidly been developed and continue to reach the market. To date, more than 183 different CE marked tests have been identified, including 131 rapid tests [8]. The pandemic having impacted both the usual distribution chains and the commercial offer, the risk of fraud and the release of products of questionable or fluctuating quality have significantly increased, leading to urgent appropriate measures by the competent authorities to control the market [9]. In order to improve the quality and provide health care professionals with clearer information of the current commercial offer, the Belgian competent national authority has therefore decided to introduce an additional step allowing tests to benefit from a specific recommendation. The participation of the manufacturers to this additional step is on a voluntary basis.

Three categories of immunoassays exist and allow, depending on the tests, to detect the presence of IgG, IgA and IgM in response to a SARS-CoV-2 infection: automated CLIA (chemiluminescent immunoassay) tests, ELISA (enzyme-linked immunosorbent assay) tests manual or automated and finally rapid immunochromatographic tests. Many hopes are based on these serological tests which could play a complementary diagnostic role to the RT-qPCR and help in answering several questions such as the deconfinement of patients according to their degree of immunity, the discrepancy of the results between CT scan and RT-qPCR, the evaluation of individual and collective immunity and allow the carrying out of large-scale epidemiological analyses. However, the lack of enough documentation of the current comparative studies does not allow a proper evaluation of the analytical and clinical performances of these different serological tests and to date, a serological reference method is still lacking.

This study carries an important epidemiological objective but is also part of the deconfinement strategy led by the testing group of the task force deployed in Belgium to manage the current health crisis. The validation of the CLIA test (LIAISON®SARS-CoV-2 IgG kit, DiaSorin®, Saluggia, Italy) described in this study responds to an official request made by this group of experts. The CLIA test (DiaSorin®), which recently obtained CE marking (04/17/2020), has another major advantage: there is already a large implementation of LIAISON XL® analyzer

(DiaSorin®) in Belgium (n=81), allowing the test to be carried out on the whole territory. The choice of automation is preferable to respond to the large number of testing needed in the next weeks.

The main objective of this study is to evaluate and compare the clinical performance of the LIAISON®SARS-CoV-2 IgG kit detecting anti-SARS-CoV-2 IgG with the ELISA test (Euroimmun Medizinische Labordiagnostika®, Lübeck, Germany) allowing the detection of anti-IgA and IgG SARS-CoV-2. This study is also the first national validation model described to date and the first study to report the performance of the LIAISON®SARS-CoV-2 IgG kit.

This validation will allow the routine implementation of a serological test in all Belgian laboratories by rationalizing its use for clinical purposes and sparing heavy validation steps consuming time, samples and reagents.

## Materials and methods

### Study design

This retrospective study was conducted from April 16 to 20, 2020 at the clinical biology laboratory of the Iris Sud Hospitals (HIS-IZZ, Brussels, Belgium). All the sera (n=125) originate from blood samples taken during previous clinical requests for diagnostic purposes and were stored in the laboratory serum biobank at  $\leq -20$  °C. Among these 125 samples, 81 samples were included in the specificity analysis. The remaining 44 samples were included in the sensitivity analysis. This study has been approved by the Ethical Committee of the HIS-IZZ (ethical agreement number: CEHIS/2020-13).

### Population

Blood samples positive for COVID-19 were collected from patients with mild, severe or critical infection based on the extent of anomalies observed on CT scan: moderate (10%–25%), extensive (25%–50%), severe (>50%) or critical >75% and on clinical symptoms (headache, fever, fatigue, cough and sore throat, myalgia, shortness of breath or digestive signs). Patients were considered positive according to the results of the RT-qPCR. The delay between the first onset of symptoms and the RT-qPCR is variable but has been estimated at 4 days ( $\pm 1$  day) in our cohort.

**Sample collection:** Blood samples were collected in serum collection tubes (BD Vacutainer SST II advance, BD, Plymouth, UK) according to standardized operating procedure. Samples were then centrifuged at 3500 rpm (2451 g) for 10 min. Serum was then collected, and samples were analyzed as soon as possible. In case the analyses were delayed, samples were aliquoted and stored between 2 and 8 °C for a maximum of 3 days. If the storage was higher than 3 days, serum sample were stored at  $\leq -20$  °C. If samples were stored

for a longer period of time at  $\leq -20^{\circ}\text{C}$ , frozen samples were thawed 1 h at room temperature on the day of the analysis. Re-thawed samples are vortexed and centrifuged before the analysis. Sera were not inactivated before measuring antibodies.

## Analytical procedures

The quantitative analysis of the anti-SARS-CoV-2 IgG antibodies directed against the subunits (S1) and (S2) of the virus spike protein was carried out using the LIAISON®SARS-CoV-2 IgG kit on a LIAISON®XL analyzer in accordance with the manufacturer's instructions. On the same day, a semi-quantitative analysis of the anti-SARS-CoV-2 IgG antibodies directed against the spike protein subunit (S1) was carried out using the ELISA method (Euroimmun Medizinische Labordiagnostika®) after specific programming on the ETI-Max 3000® controller (DiaSorin®) according to the manufacturer's instructions. For each ELISA plate, a ratio between the extinction of the serum samples and the calibrator was calculated. The interpretation criteria provided by the manufacturers are provided in Table 1.

## Evaluation of the analytical performances of the LIAISON®SARS-CoV-2 IgG kit

Evaluation of the performance was performed in accordance with the Clinical and Laboratory Standards Institute (CLSI) EP 15-A3 document [10]. The acceptance criteria were defined according to the performance reported by the manufacturer and are summarized in Table 2.

**Trueness:** Trueness has been evaluated by comparing the average value obtained on 20 replicates of two levels of quality control (QC) to the target values indicated by the manufacturer, i.e.  $<6\text{ AU/mL}$  for the low QC level and between  $15.0$  and  $45.0\text{ AU/mL}$  for the high QC level.

**Table 1:** Interpretation criteria of the CLIA LIAISON®SARS-CoV-2 IgG kit and of the ELISA method on the ETI-Max 3000® controller.

Test	Result	Interpretation
CLIA method	$<12.0\text{ AU/mL}$	Negative
	Between $12.0\text{ AU/mL}$ and $<15.0\text{ AU/mL}$	Doubtful <sup>a</sup>
	$\geq 15.0\text{ AU/mL}$	Positive
ELISA method	Ratio $<0.8$	Negative
	Ratio $\geq 0.8$ and $<1.1$	Doubtful
	Ratio $\geq 1.1$	Positive

<sup>a</sup>Procedure: For the doubtful sample with the LIAISON®SARS-CoV-2 IgG kit, the sample must be retested in duplicate. If at least two of three results are doubtful, the sample will be positive. If two of the results/three are  $<12.0\text{ AU/mL}$ , the sample will be negative.

**Precision:** Precision has been evaluated by analyzing the repeatability (expressed as intra-run CV) and the reproducibility (expressed as inter-run CV) of the method. The two levels of controls were run in triplicate for 5 consecutive days.

**Limit of blank, detection and quantification:** The diluent provided by the manufacturer was used as a blank sample to determine the limit of blank (LoB), detection (LoD) and quantification (LoQ). The LoB has been determined by running the blank sample on three separate occasions to verify that the results are well  $<1.0\text{ AU/mL}$ . The LoD and the LoQ have been determined by running 30 analyses of the blank sample using the following equations according to the SH GTA 04 document – revision 1 of the COFRAC [11].

- Limit of detection = mean of the 30 measurements +  $3 \times$  standard deviation
- Limit of quantification = mean of the 30 measurements +  $10 \times$  standard deviation

**Linearity assessment:** Linearity was evaluated according to CLSI EP-06. The patient sample with the highest concentration observed during the clinical evaluation (i.e.  $148\text{ AU/mL}$ ) was run in triplicate and then diluted by a factor of 2 on five consecutive dilutions using the diluent provided by the manufacturer. Each dilution was then run in triplicate.

**Evaluation of the carry-over:** A sample with a high level of antibodies was run in triplicate (A1, A2 and A3) followed by a negative sample also run in triplicate (B1, B2 and B3). The ratio is calculated using the following equation:  $(B1 - B3/A3 - B3) \times 100$ . Carry-over below 1% is considered satisfactory and is not linked to significant interference.

## Evaluation and comparison of the clinical performances of the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®) with the ELISA SARS-CoV-2 test system (Euroimmun Medizinische Labordiagnostika®)

**Assessment of the clinical specificity of the two serological assays:** Several samples ( $n=81$ ) were tested to assess the cross-reactivity. Seventy-three sera from COVID-19-negative patients but who had other viral, bacterial, parasitic or autoimmune pathologies that could be considered as confounding factors were included in the study. Two sera from COVID-19-negative patients but positive to another strain of coronavirus (i.e. one serum was positive to the NL63 strain and one serum was positive to the OC43 strain) were analyzed. Sera positive for the following viral, bacterial and infection from parasite origin were included to assess the possible cross-reactivity: HBsAg ( $n=7$ ), HAV IgM ( $n=3$ ), adenovirus ( $n=1$ ), HSV IgM and CMV IgM ( $n=1$ ), IgM CMV ( $n=8$ ), IgM parvovirus B19 ( $n=5$ ), HIV ( $n=1$ ), ASLO (antistreptolysin O) ( $n=4$ ), anti-*Treponema pallidum* antibody ( $n=1$ ), IgG *Borrelia* ( $n=1$ ), IgM *Mycoplasma pneumoniae* ( $n=10$ ), *Toxoplasma gondii* IgM ( $n=16$ ). The cross-reactivity of the following autoimmune pathologies was also assessed: rheumatoid factor ( $n=1$ ), anti-TPO antibody ( $n=7$ ), RAI (search for irregular agglutinins) ( $n=4$ ), direct coombs ( $n=1$ ). Finally, one serum with a high level of total IgM ( $9.01\text{ g/L}$ ) (normal range:  $0.40\text{--}2.30\text{ g/L}$ ), one serum with high total IgA ( $4.47\text{ g/L}$ ) (normal range:  $0.70\text{--}4.00\text{ g/L}$ ) and six sera from COVID-19-negative healthy subjects with no history

**Table 2:** Acceptance criteria for the evaluation of the analytical performances of the LIAISON®SARS-CoV-2 IgG kit.

Validation step	Acceptance criteria according to the manufacturer performances	Results
Trueness	Low QC level: <6 AU/mL High QC level: between 15.0 and 45.0 AU/mL	Low QC level: $0.06 \pm 0.01$ AU/mL High QC level: $30.15 \pm 0.86$ AU/mL
Precision	Repeatability: <sup>a</sup> Low QC level: $\leq 3.3\%$ High QC level: $\leq 5.3\%$ Reproducibility: <sup>a</sup> Low QC level: $\leq 3.7\%$ High QC level: $\leq 11.1\%$	Repeatability: Low QC level: 3.4% High QC level: 3.6% Reproducibility: Low QC level: 5.1% High QC level: 4.7%
Limit of blank	Not reported by the manufacturer	$0.06 \pm 0.03$ AU/mL
Limit of detection	3.8 AU/mL	0.11 AU/mL
Limit of quantification	Not reported by the manufacturer	0.24 AU/mL
Linearity	Linear regression	Polynomial regression
Carry-over	Not reported by the manufacturer	0.01%
Specificity	Cut-off of the manufacturer $\geq 99\%$	Cut-off of the manufacturer 100% Adapted cut-off ( $>6.1$ AU/mL) 99%
Sensitivity after 2 weeks	Cut-off of the manufacturer 97%	Cut-off of the manufacturer 91% Adapted cut-off ( $>6.1$ AU/mL) 100%

<sup>a</sup>The results refer to the groups of samples investigated and are not guaranteed specifications, as differences may exist between laboratories and locations. These have to be considered as indicative values.

of known autoimmune pathologies and without any acute infection of viral or bacterial origin were included in the study. In these six sera, residues from old viral infections were present: IgG parvovirus B19 ( $n=1$ ), VCA and IgG CMV ( $n=2$ ), IgG HZV and IgG Rubella ( $n=2$ ), HBV antibody ( $n=1$ ). All these samples were collected in 2019 before the start of the COVID-19 outbreak and were stored at  $-20^\circ\text{C}$ .

**Assessment of the clinical sensitivity of the two serological assays:** A total of 44 sera collected at  $\geq 14$  days since the date of the confirmation of the diagnostic by RT-qPCR were analyzed to assess the clinical sensitivity.

## Statistical analyses

Statistical analyses were carried out using MedCalc version 10.4.0.0 (MedCalc Software, Ostend, Belgium). Descriptive statistics were used to analyze the data. Sensitivity was defined as the proportion of correctly identified COVID-19-positive patients who were initially positive by RT-qPCR SARS-CoV-2 determination in respiratory samples. Specificity was defined as the proportion of naive participants who were classified as positive as analyzed by one of the two methods tested in this study. The clinical performance of the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®) and of the ELISA methods (Euroimmun Medizinische Labordiagnostika®) was examined using receiver operator characteristic (ROC) curves. The ROC area under the curve (AUC) was calculated as the fraction true positive and false positive determined according to the manufacturer's cut-off values for positive results.

## Results

### Evaluation of the analytical performances of the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®)

#### Trueness

The low QC level showed a mean value of  $0.06 \pm 0.01$  AU/mL over the 20 samples tested. The high QC level showed a mean value of  $30.15 \pm 0.86$  AU/mL. These results agree with the acceptance criteria and are in line with specifications provided by the manufacturer. However, the manufacturer does not provide a degree of uncertainty for its two QC levels but only reports a range, preventing a proper assessment of the trueness. Therefore, when available, trueness should be estimated with other methods or experiments.

#### Precision

Table 2 summarizes the repeatability and reproducibility results. These results agree with the acceptance criteria and are in line with the CVs provided by the manufacturer.



The intra- and inter-run CVs were within the range reported by the manufacturer for the two levels of QC, except for the reproducibility for the low QC level (3.7% as reported by the manufacturer vs. 5.1% as reported by this validation study).

### Limit of blank, detection and quantification


The LoB, LoD and LoQ are  $0.06 \pm 0.03$  AU/mL, 0.11 AU/mL and 0.24 AU/mL, respectively. Only the LoD is reported by the manufacturer, i.e. 3.8 AU/mL, and the LoD calculated by the user according to the CLSI EP17-A2 document is far below this value which is in agreement with the acceptance criteria [12].

### Linearity

Results from the linearity study are reported in Figure 1. A regression analysis for second-order polynomials was performed. The regression equation was:  $y = 37.73 + 1.60x - 0.006x^2$ . No statistically significant difference was observed between the measured and expected values ( $p < 0.001$ ).

### Carry-over


The following values have been obtained for the different samples and the different runs: A1 = 146 AU/mL, A2 = 140 AU/mL, A3 = 145 AU/mL, B1 = 0.275 AU/mL, B2 = 0.282 AU/mL and B3 = 0.291 AU/mL. The carry-over is 0.01%.



**Figure 1:** Linearity assessment for the LIAISON®SARS-CoV-2 S1/S2 IgG antibody assay.

### Evaluation and comparison of the clinical performances of the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®) with the ELISA SARS-CoV-2 test system (Euroimmun Medizinische Labordiagnostika®)

Among the 125 samples evaluated 2 weeks after the RT-qPCR positive detection, and according to manufacturer's cut-off, the LIAISON®SARS-CoV-2 IgG kit identified 40 true positives and 81 true negatives. Four samples were classified as false negative and none as false positive (Figure 2). On the same cohort, the ELISA SARS-CoV-2 test identified 42 true positives and 79 true negatives. Two samples were false positive, and two samples were false negative. The specificity and the sensitivity were 100% (95% CI: 95%–100%) and 91% (95% CI: 79%–96%), and



**Figure 2:** LIAISON®SARS-CoV-2 and ELISA SARS-CoV-2 IgG antibody performance at more than 2 weeks after a positive RT-qPCR determination (n = 125 samples).

Data distribution obtained for negative and positive samples. Lines represent median values with interquartile range.

98% (95% CI: 91%–99%) and 96% (95% CI: 85%–99%) for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively, using the cut-off provided by the manufacturer. The kappa index was 0.93 for the two tests.

The cut-offs provided by the ROC curve analyses (i.e.  $>6.1$  and  $>0.708$  for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively) improve the performance of the tests. Among the 125 samples tested, the use of these adapted cut-offs permits the correct reclassification of the four false-negative cases with the LIAISON®SARS-CoV-2 IgG kit to the detriment of one false-positive case. For the ELISA SARS-CoV-2 test, the use of the adapted cut-offs permitted the correct reclassification of the two false-negative cases to the detriment of one false-positive case ( $n=3$  in total). The specificity and sensitivity were 99% (95% CI: 93%–100%) and 100% (95% CI: 92%–100%), and 96% (95% CI: 90%–96%) and 100.0% (95% CI: 92%–100%) (Figure 3) and the kappa index was 0.98 and 0.95 for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively, using the adapted cut-offs. There was no statistically significant difference between the two tests in terms of clinical performance ( $p=0.493$ ).


### Assessment of clinical specificity

From the results obtained above, interference from certain antibodies or antigens produced following viral, bacterial

or parasitic infections or following autoimmune pathologies reveals to be relatively low with a specificity of 99% (95% CI: 93%–100%) and 96% (95% CI: 90%–96%) for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively, using the adapted cut-offs. Using the cut-offs provided by the manufacturers, the specificity was 100% (95% CI: 95%–100%) and 98% (95% CI: 91%–99%), a result not statistically and clinically different from the adapted cut-off.

## Discussion

This study is the first to describe the analytical and clinical performances of the LIAISON®SARS-CoV-2 IgG kit from DiaSorin® in comparison with the ELISA method from Euroimmun Medizinische Labordiagnostika®, the first ELISA testing that reached the market for the quantitative assessment of IgG and IgA directed against the spike protein subunit (S1). Only one study has previously evaluated the analytical performance of another CLIA test, the MAGLUMI™ 2000 Plus (New Industries Biomedical Engineering Co®, Shenzhen, China) but this was on a smaller cohort of patients and samples and this study did not compare the performance of the CLIA assay with another test [13]. Also, regardless of the technique used (CLIA vs. ELISA), it is important to note that there is a difference in terms of antigenic targets. Namely, the DiaSorin® kit provides an additional antibody detection target with the S2 protein which is involved in the virus fusion machinery



**Figure 3:** LIAISON®SARS-CoV-2 and ELISA SARS-CoV-2 IgG antibody performance at more than 2 weeks after a positive RT-qPCR determination ( $n=125$  samples).

The adapted cut-offs were the following:  $>6.1$  for the DiaSorin assay and  $>0.708$  for the Euroimmun assay. ROC curves reported excellent specificity and sensitivity of 99% (95% CI: 93–100%) and 100% (95% CI: 92–100%), and 96% (95% CI: 90–96%) and 100.0% (95% CI: 92–100%) for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively, using the adapted cut-offs.

while the kit from Euroimmun Medizinische Labordiagnostika® only detects the S1 protein.

The analytical and clinical performances of the LIAISON®SARS-CoV-2 satisfied all the acceptance criteria and provided “real world” analytical and clinical performances very close to the ones reported by the manufacturer in its insert kit with the exception of the reproducibility for the low QC level, i.e. 3.7% as reported by the manufacturer vs. 5.1% as reported by this validation study. However, an inter-assay CV around 5% is considered sufficient. Also, regarding the assessment of the trueness, the manufacturer does not provide a degree of uncertainty for its two QC levels but only reports a range, preventing adequate comparison. Therefore, when available, trueness should be estimated with other methods or experiments. Evaluation of the LoQ has not been determined using the 20% CV method due to the high reagent consumption such an evaluation requires. Comparison of this method of LoQ determination with the results obtained by the 10\*SD method as performed in this study has to be done to confirm our results.

Comparison between the LIAISON®SARS-CoV-2 and the ELISA method did not reveal any difference between the two techniques in terms of sensitivities and specificities regarding the determination of the IgG. However, based on the cut-off provided by the manufacturers, two results were considered doubtful with the LIAISON®SARS-CoV-2 while one sample was considered doubtful with the ELISA methods. Adaptation of cut-off as determined by the ROC curve analyses highly improved the clinical performances of the tests from the second week following the positive RT-qPCR determination, with a sensitivity of 100% and a specificity of 99%. In comparison, adaptation of the cut-off for the ELISA SARS-CoV-2 test showed a sensitivity of 100% and a specificity of 96% on the same set of samples suggesting that, by adapting the cut-off, the LIAISON®SARS-CoV-2 shows at least, if not better, performances than the ELISA testing. The results obtained during this study confirm previous observation that the production of IgG is detectable in symptomatic patients from the second week following the positive RT-qPCR determination [14]. We recommend each center to reestablish their own cut-off to improve the clinical performance and avoid false-negative results. Other studies have found significant differences in sensitivity when comparing the ELISA SARS-CoV-2 test from Euroimmun Medizinische Labordiagnostika® with other ELISA tests. According to the study by Lassaunière et al. conducted on 111 patients, the Wantai®SARS-CoV-2 test (Wantai Biological Pharmacy Enterprise®, Beijing, China), which detects total antibodies, showed a specificity of 100% and a sensitivity of 90%

while the test from Euroimmun Medizinische Labordiagnostika® revealed a specificity of 96% and a sensitivity of 65% [15].

### **Specificity of IgG antibody detection in samples with known antibodies directed against different targets**

Using the adapted cut-offs, only one false-positive sample (i.e. a sample positive for AgHBs) was detected with the LIAISON®SARS-CoV-2 while three false positives were reported with the ELISA technique. The sera that resulted in a cross-reaction showed anti-TPO antibodies (n=1), anti-HAV IgM (n=1) and ASLO (n=1). Other studies have also observed false positives with the same ELISA method and reported interference with sera positive for IgM directed against anti-influenza A, -influenza B, anti-adenovirus and anti-hCoV-HKU1 [15, 16]. According to the cross-reactivity studies described in the insert kit of the LIAISON®SARS-CoV-2, three samples out of 168 analyzed also showed cross-reactivity with samples positive for anti-HBV (n=1), anti-influenza (n=1) and rheumatoid factor (n=1). Although we have not tested the interference potential of anti-influenza A and B antibodies, we have observed probable new interference with anti-TPO antibodies (n=1), anti-HAV IgM (n=1) and ASLO (n=1). Another limitation of our cross-reaction study is related to the very low number of antibody positive sera from other viruses of the Coronaviridae family. Given the rarity of these samples, only antibodies specifically directed against the NL63 and OC43 viruses were tested and did not show cross-reactivity.

### **Choice of the technique to determine the presence of IgG antibodies and clinical relevance**

To date, an IgG protection threshold has not yet been demonstrated. However, if such a threshold should be established soon, the ELISA technique will probably be less efficient in determining a protection index as it is a semi-quantitative method, but additional data will be necessary to confirm this assumption. However, from a practical point of view, the LIAISON®SARS-CoV-2 assay offers a rate of random access tests of up to 170 tests/h while the ELISA technique from Euroimmun Medizinische Labordiagnostika® adapted on the ETI-max 3000® controller has more limited capacities with less flexible batch work and up to 160 tests/day but it integrates the possibility to combine the analysis of both IgA and IgG.



The validation of SARS-CoV-2 serological methods is currently crucial to detect patients exposed to the virus including asymptomatic patients, to provide missing epidemiological data in Belgium and other countries and potentially be able to detect a protective IgG threshold in the population. Serological testing carried out in the population will also be a very useful epidemiological information to compare the immunological status of a population with other countries and perhaps help in the development of a predictive visualization on the evolution of the epidemic. Routine use of this technique will also allow other serological studies to be carried out based on well-targeted population clusters in the hope of announcing the end of the pandemic when 50%–60% of the population have been in contact with the virus [17]. In addition to this deconfinement strategy, serological tests will also assess the potential effectiveness of vaccine trials and antibody-mediated therapies [18, 19].

## Conclusions

In conclusion, this study is the first to report the validation of a new CLIA test, the LIAISON®SARS-CoV-2 from DiaSorin® allowing to detect IgG antibodies specifically directed against SARS-CoV-2. The analytical and clinical performances are excellent, especially after adapting the cut-offs of the assays, and the automation of the test offers important rates, ideal for absorbing an extension of testing.

**Acknowledgments:** The sera with antibodies against NL63 and OC43 viruses were kindly provided by Professor Elizabeth Padalko, University Hospital Ghent. The authors also thank all the clinical laboratory staff for technical assistance.

**Research funding:** None declared.

**Author contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** Authors state no conflict of interest.

**Ethical approval:** The study was approved by the ethical committee of the Iris Hospitals South.

## References

1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514–23.
2. Coronavirus Resource Center. <https://coronavirus.jhu.edu/map.html>. Accessed: 06 May 2020.
3. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 106, 2020.
4. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. *medRxiv* 2020.
5. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect* 2020;9:386–9.
6. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. *Radiology* 2020:200343.
7. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology* 2020:200642.
8. Sars-CoV-2 Diagnostics Pipeline. <https://www.finddx.org/covid-19/pipeline/>. Accessed: 23 April 2020.
9. Newton PN, Bond KC. 53 signatories from countries. COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. *Lancet Glob Health* 2020. doi:10.1016/S2214-109X(20)30136-4.
10. CLSI. User Verification of Precision and Estimation of Bias; Approved Guideline – Third Edition. CLSI Document EP15-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
11. Cofrac. Guide Technique d'Accréditation de Vérification (Portée A)/Validation (Portée B) des Méthodes en Biologie Médicale – Document SH GTA 04 (révision 01), 2015.
12. CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – 2nd Edition. CLSI Document EP17-A2 2012; Wayne, PA: Clinical and Laboratory Standards Institute.
13. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. *Clin Chem Lab Med* 2020. doi:10.1515/cclm-2020-0443.
14. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. *Int J Infect Dis* 2020;94:49–52.
15. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* 2020;2020.04.09.20056325.
16. Okba NM, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2- specific antibody responses in coronavirus disease 2019 patients. *Emerg Infect Dis* 2020. doi:10.3201/eid2607.200841.
17. Joint European Roadmap towards lifting COVID-19 containment measure. [https://ec.europa.eu/info/sites/info/files/communication\\_-\\_a\\_european\\_roadmap\\_to\\_lifting\\_coronavirus\\_containment\\_measures\\_0.pdf](https://ec.europa.eu/info/sites/info/files/communication_-_a_european_roadmap_to_lifting_coronavirus_containment_measures_0.pdf). Accessed: 24 Apr 2020.
18. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. *J Clin Invest* 2020;130:1545–8.
19. Madore DV, Meade BD, Rubin F, Deal C, Lynn F, Meeting C. Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. *Vaccine* 2010;28:4539–47.